Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,583 matching trials from the live ClinicalTrials.gov search.
Conditions
Type 2 Diabetes
Interventions
High Intensity, Low Intensity
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
9 Years to 11 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Oakland, California
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1b Study of DCR-AUD in Healthy Volunteers

NCT05845398
Conditions
Alcohol Use Disorder
Interventions
DCR-AUD, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
21 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Mindfulness for Smoking Cessation

NCT02943499
Conditions
Smoking Cessation
Interventions
App/Training, Smartphone
Behavioral · Device
Lead sponsor
Brown University
Other
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Completed Not applicable Interventional Results available

Efficacy of Gamification in Enhancing User Engagement

NCT05422339
Conditions
Alzheimer Disease, Dementia, Gamification, Assistive Technology
Interventions
The MapHabit system (MHS)
Device
Lead sponsor
MapHabit, Inc.
Industry
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Medullary Thyroid Carcinoma
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
93,600,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Parsippany, New Jersey
Conditions
Post Traumatic Stress Disorder
Interventions
Modius Spero active device, Sham device
Device
Lead sponsor
Neurovalens Ltd.
Industry
Eligibility
22 Years to 80 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Conditions
Heart Failure, Caregiver
Interventions
HEROIC program, Active Comparator Control 1
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Denver, Colorado • Baltimore, Maryland
Conditions
Schizophrenia
Interventions
Lurasidone, Quetiapine XR, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 23 more
Completed Not applicable Interventional Accepts healthy volunteers

Aromatherapy for Improving Post-Surgical Quality of Life

NCT04800744
Conditions
Quality of Life, Anxiety Postoperative
Interventions
Lavender peppermint elequil aromatab, Sweet almond oil elequil aromatab
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Results available

Ramelteon in the Prevention of Post-operative Delirium

NCT02324153
Conditions
Delirium, Delirium, Dementia, Amnestic, Cognitive Disorders, Delayed Emergence From Anesthesia, Cognitive Disorders
Interventions
Ramelteon, Microcrystalline Cellulose, Riboflavin 100 mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Early Phase 1 Interventional Accepts healthy volunteers

Precision Functional Brain Mapping in Psilocybin

NCT04501653
Conditions
Psilocybin
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Intermediate
Interventions
Sham Injector, FAI Insert
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
Interventions
Xtressé Hair Growth Gummies, Placebo Comparator
Other · Dietary Supplement
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Port Orange, Florida
Conditions
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Sham Intervention, Survey Administration, Transcranial Direct Current Stimulation
Procedure · Other · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase, porcine (pig) PERT
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
32
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 28 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more
Conditions
Advanced Cancer
Interventions
Nivolumab, Dasatinib, Relatlimab, Ipilimumab, BMS-986205
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 26 more
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo
Biological · Drug
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Anaheim, California • Orange, California • Denver, Colorado + 4 more
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of Hemp-Derived Cannabinoids on Menopause Symptoms

NCT07393672
Conditions
Menopause, Perimenopause
Interventions
Hemp-derived cannabinoids, Placebo
Drug
Lead sponsor
Washington State University
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Pullman, Washington
Conditions
Adjustment Disorders, Mental Disorder
Interventions
Transdiagnostic Behavior Therapy (TBT), Treatment as Usual-Problem Solving Therapy (TAU-PST)
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Chronic Low Back Pain
Interventions
Pregnenolone, DHEA, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Autism Spectrum Disorders
Interventions
Syntocinon (synthetic oxytocin), Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Diabetic Macular Edema (DME)
Interventions
4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
60
States / cities
Scottsdale, Arizona • Encino, California • Fullerton, California + 53 more
Active, not recruiting Phase 2 Interventional

Study of SPG302 in Adults With Schizophrenia

NCT06442462
Conditions
Schizophrenia
Interventions
SPG302, Placebo
Drug
Lead sponsor
Spinogenix
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Garden Grove, California